Bookmarks
Natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients: a cohort study
Safe People
Organisation name
University of Oxford
Organisation sector
Academic Institute
Applicant name(s)
Daniel Prieto-Alhambra - Chief Investigator - University of OxfordEdward Burn - Corresponding Applicant - Oxford University HospitalsAntonella Delmestri - Collaborator - University of OxfordNathan Jones - Collaborator - University of Oxford
Safe Projects
Project ID
CPRD23
Lay summary
People with coronavirus disease-2019 (COVID-19) may be at a high risk of thrombotic disease, where blood clots block veins or arteries. There is a need to better understand how common these thromboembolic events among patients with COVID-19 are, their implications for health outcomes, and whether individuals with a particularly high risk for them can be identified.
Technical summary
We will investigate the risks of thromboembolic and rare coagulopathy events among patients with COVID-19, the impact of thromboembolic events on prognosis in COVID-19, the association between various risk factors and rates of thromboembolic events, and to develop and externally validate prediction models for thromboembolic events for patients with COVID-19.
Latest approval date
07/05/2021
Safe Data
Dataset(s) name
HES Admitted Patient Care
ONS Death Registration Data
Patient Level Index of Multiple Deprivation
Safe Setting
Access type
Release